Zhang Y, Zhu W, Tao R, Li W, Jiang C, Yan X
J Transl Med. 2025; 23(1):116.
PMID: 39863860
PMC: 11763126.
DOI: 10.1186/s12967-025-06091-4.
Dizibuyuk O, Bozdag Z, Karakok M
Diagnostics (Basel). 2025; 15(1.
PMID: 39795582
PMC: 11719943.
DOI: 10.3390/diagnostics15010053.
Bueno A, Stein M, Runcie K
Transl Cancer Res. 2024; 13(11):6448-6462.
PMID: 39697753
PMC: 11651811.
DOI: 10.21037/tcr-23-2247.
Carmignani L, Guzzo S, Baudo A, Nazzani S, Bonacina E, Silvani C
World J Urol. 2024; 43(1):14.
PMID: 39630229
DOI: 10.1007/s00345-024-05359-6.
Alomari A, Obri M, Aldroubi B, Khan M, Chaudhary A, Althunibat I
ACG Case Rep J. 2024; 11(11):e01548.
PMID: 39493953
PMC: 11527420.
DOI: 10.14309/crj.0000000000001548.
Integration of proteomics and transcriptomics to construct a prognostic signature of renal clear cell carcinoma.
Cheng G, Zhou Z, Li S, Ye Z, Wang Y, Wen J
Int J Med Sci. 2024; 21(11):2215-2232.
PMID: 39239554
PMC: 11373548.
DOI: 10.7150/ijms.99992.
Turning the tide: pembrolizumab's triumph in adjuvant RCC therapy.
Attieh F, Boutros M, Kourie H, Mahrous M
Med Oncol. 2024; 41(10):242.
PMID: 39237796
DOI: 10.1007/s12032-024-02486-3.
Prognostic value of KLFs family genes in renal clear cell carcinoma.
Fu M, Du Y, Liu F, Xiao J, Zhang L, Zeng Y
Sci Rep. 2024; 14(1):20204.
PMID: 39215019
PMC: 11364764.
DOI: 10.1038/s41598-024-69892-5.
Bilateral Renal Cell Carcinoma in the Horseshoe Kidney With Metastasis in Gallbladder, Pancreas and Duodenum: A Report of a Rare Case and Literature Review.
Ratnaparkhi C, Dhok A, Kumar N, Pande S, Jeswani S
Cureus. 2024; 16(4):e58363.
PMID: 38756314
PMC: 11096990.
DOI: 10.7759/cureus.58363.
Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.
Aguilar K, Sharma A, Yang T, Mehta D, Panda C, Lokeshwar V
J Cell Signal. 2024; 5(2):51-56.
PMID: 38726221
PMC: 11081427.
DOI: 10.33696/signaling.5.112.
MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
Liu Y, Qi L, Ye B, Wang A, Lu J, Qu L
Cancer Biol Ther. 2024; 25(1):2345977.
PMID: 38659199
PMC: 11057626.
DOI: 10.1080/15384047.2024.2345977.
Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.
Domanski P, Jarosinska J, Kruczyk B, Pietak M, Mydlak A, Demkow T
Contemp Oncol (Pozn). 2024; 27(4):242-248.
PMID: 38405212
PMC: 10883196.
DOI: 10.5114/wo.2023.134786.
A Rare Site of Metachronous Metastases from Renal Cell Carcinoma.
Nutakki M, Murhekar K, Sundersingh S, Raja A
J Kidney Cancer VHL. 2024; 11(1):1-4.
PMID: 38213482
PMC: 10777059.
DOI: 10.15586/jkcvhl.v11i1.282.
Predictors of disease recurrence in high-risk non-metastatic renal cell carcinoma patients post-surgical resection A single-center, retrospective study.
Taneja S, Bonert M, Hoogenes J, Matsumoto K, Shayegan B, Matsumoto E
Can Urol Assoc J. 2023; 18(3):E53-E58.
PMID: 37931279
PMC: 10954279.
DOI: 10.5489/cuaj.8449.
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies.
da Silva Prade J, DE Souza R, da Silva DAvila C, da Silva T, Livinalli I, Bertoncelli A
Cancer Diagn Progn. 2023; 3(6):616-634.
PMID: 37927802
PMC: 10619564.
DOI: 10.21873/cdp.10264.
Role of perioperative immunotherapy in localized renal cell carcinoma.
Kaur J, Patil G, Geynisman D, Ghatalia P
Ther Adv Med Oncol. 2023; 15:17588359231181497.
PMID: 37529159
PMC: 10387776.
DOI: 10.1177/17588359231181497.
A Comprehensive Study on Signal Transduction and Therapeutic Role of miR-877 in Human Cancers.
Rafat M, Kohsarian M, Bahiraei M, Nikpoor A
Adv Biomed Res. 2023; 12:118.
PMID: 37434921
PMC: 10331537.
DOI: 10.4103/abr.abr_412_21.
Establishing a prognostic model based on five starvation-related long non-coding RNAs for clear cell renal cell carcinoma.
Yu Z, Chen G, Feng Z, Li Y, Yu H, Shi W
Aging (Albany NY). 2023; 15(14):6736-6748.
PMID: 37341994
PMC: 10415547.
DOI: 10.18632/aging.204816.
Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma.
Stout M, Thaper A, Xu V, Singer E, Saraiya B
J Cancer Immunol (Wilmington). 2023; 5(1):5-12.
PMID: 37292242
PMC: 10249482.
DOI: 10.33696/cancerimmunol.5.072.
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial.
Ali M, Wood S, Pryor D, Moon D, Bressel M, Azad A
Contemp Clin Trials Commun. 2023; 33:101145.
PMID: 37168818
PMC: 10164766.
DOI: 10.1016/j.conctc.2023.101145.